AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31

AGIOS PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$34.90+3.58 (+11.43%)

Close on Oct 19, 2026

Market cap: $2.08B
P/E (TTM): –
Dividend yield: –

AGIOS PHARMACEUTICALS, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Stock-Based Compensation	58	57	53	49	48	45	43	46	44	44	45	42	44	44	49	49	50	54	54	55	58	61	62	51	55	56	58	73	79	77	73	68	56	52	48	45	45	44	42	42
Change in Accounts Receivable	-15	-13	-6.47	-1.91	-1.22	0.11	-1.30	-1.94	-1.51	-1.68	-0.60	0.64	-0.65	-1.24	-2.21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.29	2.95	2.93	2.56	1.55	-2.55	0.28	-0.11
Change in Inventory	0.70	-5.48	-5.30	-5.61	-6.91	-6.54	-8.54	-9.16	-8.27	-12	-11	-12	-12	-8.89	-8.49	-5.18	-4.06	-2.49	0	4.04	3.90	2.45	0	-5.52	-6.57	-7.45	-6.46	-4.99	-4.66	-2.33	-0.87	-0.86	–	–	0	–	–	–	–	–
Change in Accounts Payable	-1.25	-0.43	1.75	2.14	7.42	2.35	6.60	3.83	-1.63	2.49	-8.73	2.86	3.84	-1.35	3.44	0.57	0.18	-0.20	1.86	3.05	0.33	1.27	3.33	-1.54	3.47	8.22	4.16	2.99	-1.16	-5.96	-5.49	-1.24	-5.80	1.85	5.33	2.58	4.68	2.80	3.50	7.21
Change in Unearned Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-26	-28	-27	-40	-36	170	166	181
Operating Cash Flow	-361	-380	-373	-410	-406	-401	-390	-329	-307	-301	-296	-290	-299	-307	-309	-327	-341	-384	-407	-373	-356	-306	-291	-335	-352	-373	-371	-351	-329	-309	-304	-305	-319	-310	-285	-262	-233	-17	39	59
Capital Expenditures	-4.66	-4.32	-4.32	-4.16	-3.03	-2.31	-1.69	-0.95	-0.90	-0.74	-1.00	-0.88	-0.55	-2.48	-4.88	-9.27	-9.21	-7.53	-5.74	-1.80	-7.03	-11	-14	-20	-17	-14	-12	-6.40	-7.50	-7.59	-6.99	-7.21	-6.09	-5.77	-4.63	-4.57	-5.98	-7.68	-9.92	-11
Divestitures	–	–	0	–	–	–	200	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Purchase of Investments	-636	-615	-642	-679	-1,500	-1,473	-1,542	-1,435	-534	-534	-418	-576	-656	-803	-1,031	-1,209	-1,487	-1,672	-1,378	-1,078	-866	-564	-557	–	–	–	–	–	–	–	–	-840	-813	-993	-689	-743	-748	-322	-506	-502
Investing Cash Flow	367	406	377	238	393	351	363	508	297	307	240	227	292	327	243	66	-271	-652	1,249	1,415	1,521	1,842	76	-180	26	68	91	263	186	25	-274	-219	-156	-335	-58	-177	-306	5.03	-119	-21
Share Repurchases	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	-802	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Stock Issued	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	277	0	0	0	516	516	516	786	270	270	432	–	162	–
Financing Cash Flow	12	9.14	8.68	11	9.16	10	14	10	9.69	8.83	5.43	4.61	3.91	3.61	2.35	-16	-268	-772	-766	-747	-492	263	262	539	538	290	290	13	17	23	546	548	546	809	285	287	444	173	170	167
Net Change in Cash	19	35	13	-161	-3.65	-40	-12	189	-0.24	15	-51	-58	-3.79	24	-64	-278	-881	-1,808	76	295	673	1,799	47	23	212	-14	10	-75	-127	-261	-32	24	72	164	-58	-153	-95	161	89	205
Free Cash Flow	-365	-385	-377	-414	-409	-404	-392	-330	-307	-301	-297	-291	-300	-309	-314	-337	-350	-392	-413	-374	-363	-317	-305	-355	-369	-387	-383	-358	-337	-316	-311	-312	-325	-316	-290	-267	-239	-24	29	48
Income Taxes Paid	-0.80	0.44	0.63	45	45	44	43	-0.65	0.17	1.04	1.57	-0.35	-1.04	-1.84	0	9.10	12	18	16	8.92	6.20	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 92.0%
Operating margin: -466.8%
Net margin: -418.2%
Return on equity, FY2025: -30.2%

Financial strength

Current ratio: 10.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 141.9%

Valuation

P/E ratio: –
Price to sales: 21.11
Price to book: 2.02
Dividend yield: –